Impact of measurable residual disease status on outcomes of acute myeloid leukemia and patients 18-65 years old in first complete remission undergoing allogeneic hematopoietic cell transplantation.
Study #: LK21-01a
Study Status: Published
Presentation(s)
2024, EHA (Oral)